General Court upholds Lundbeck pay-for-delay fine
Fines of nearly €150 million imposed on pharmaceutical company Lundbeck and a number of generic rivals by the European Commission have been upheld by the EU General Court. The Court's decisions are the first to find that pay-for-delay agreements breach EU antitrust rules
The cases concerned agreements between Lundbeck and four generic companies - Generics UK, Arrow, Alpharma and Ranbaxy.
The agreements all provided that Lundbeck would pay the generic companies not to produce competing versions of its antidepressant drug citalopram (branded as...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.